2019年系统性红斑狼疮研究新进展

doi:10.35541/cjd.20200013

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (2): 183-186.doi: 10.35541/cjd.20200013

• 综述 • 上一篇

2019年系统性红斑狼疮研究新进展

罗帅寒天龙海张桂英陆前进

中南大学湘雅二医院皮肤科，长沙 410011

收稿日期:2020-01-03 修回日期:2020-04-29 发布日期:2021-01-29
通讯作者: 陆前进 E-mail:qianlu5860@csu.edu.cn
基金资助:
国家自然科学基金（81703133、81773334）；湖南省科技创新计划项目（2018RS3031）；长沙市科技计划项目（KQ1802002）

Advances in systemic lupus erythematosus in 2019

Luo Shuaihantian, Long Hai, Zhang Guiying, Lu Qianjin

Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha 410011, China

Received:2020-01-03 Revised:2020-04-29 Published:2021-01-29
Contact: Lu Qianjin E-mail:qianlu5860@csu.edu.cn
Supported by:
National Natural Science Foundation of China （81703133, 81773334）; Hunan Science and Technology Innovation Project （2018RS3031）; Changsha Science and Technology Planning Project （KQ1802002）

摘要/Abstract

摘要： 【摘要】系统性红斑狼疮是一种主要累及中青年女性的自身免疫性疾病，临床表现复杂多样，可累及多器官系统。系统性红斑狼疮病因、诊断与治疗的研究一直是该领域的热点。2019年，国内外研究者在其发病机制、诊断和评估以及治疗方面取得了一系列新进展，本文就主要代表性成果进行综述。

关键词: 红斑狼疮, 系统性, 受体, Fc, 程序性细胞死亡受体1, 贝利尤单抗

Abstract: 【Abstract】 Systemic lupus erythematosus （SLE） is an autoimmune disease that mainly affects young and middle-aged women. It can involve multiple organ systems, with complex and diverse clinical manifestations. The research on the etiology, diagnosis and treatment of SLE has always been a hot spot in this field. In 2019, a lot of new progress was made in the pathogenesis, diagnosis and evaluation, and treatment of SLE in China and other countries, and this review summarizes main representative results.

Key words: Lupus erythematosus, systemic, Receptors, Fc, Programmed cell death 1 receptor, Belimumab

罗帅寒天龙海张桂英陆前进. 2019年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021,54(2):183-186. doi:10.35541/cjd.20200013

Luo Shuaihantian, Long Hai, Zhang Guiying, Lu Qianjin. Advances in systemic lupus erythematosus in 2019[J]. Chinese Journal of Dermatology, 2021, 54(2): 183-186.doi:10.35541/cjd.20200013

参考文献 31

［1］	罗帅寒天, 龙海, 陆前进. 2018年系统性红斑狼疮研究新进展［J］. 中华皮肤科杂志, 2020,53（8）:665⁃667. doi: 10.35541/cjd. 20190298.
［2］	陆前进, 罗帅寒天. 系统性红斑狼疮的诊疗进展［J］. 中华皮肤科杂志, 2018,51（1）:1⁃4. doi: 10.3760/cma.j.issn.0412⁃4030. 2018.01.001.
［3］	Smith KG, Clatworthy MR. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications［J］. Nat Rev Immunol, 2010,10（5）:328⁃343. doi: 10.1038/nri2762.
［4］	Hu W, Zhang Y, Sun X, et al. FcγRIIB⁃I232T polymorphic change allosterically suppresses ligand binding［J］. Elife, 2019,8doi: 10.7554/eLife.46689.
［5］	Alsaab HO, Sau S, Alzhrani R, et al. PD⁃1 and PD⁃L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome［J］. Front Pharmacol, 2017,8:561. doi: 10.3389/fphar.2017.00561.
［6］	Han X, Vesely MD, Yang W, et al. PD⁃1H （VISTA）⁃mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus［J］. Sci Transl Med, 2019,11（522）. doi: 10.1126/scitranslmed.aax1159.
［7］	Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease［J］. Nature, 2016,535（7610）:75⁃84. doi: 10.1038/nature18848.
［8］	Azzouz D, Omarbekova A, Heguy A, et al. Lupus nephritis is linked to disease⁃activity associated expansions and immunity to a gut commensal［J］. Ann Rheum Dis, 2019,78（7）:947⁃956. doi: 10.1136/annrheumdis⁃2018⁃214856.
［9］	Wu H, Huang X, Qiu H, et al. High salt promotes autoimmunity by TET2⁃induced DNA demethylation and driving the differentiation of Tfh cells［J］. Sci Rep, 2016,6:28065. doi: 10. 1038/srep28065.
［10］	Zhang D, Jin W, Wu R, et al. High glucose intake exacerbates autoimmunity through reactive⁃oxygen⁃species⁃mediated TGF⁃β cytokine activation［J］. Immunity, 2019,51（4）:671⁃681.e5. doi: 10.1016/j.immuni.2019.08.001.
［11］	Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis［J］. Nat Rev Cancer, 2011,11（1）:23⁃34. doi: 10.1038/nrc2986.
［12］	Fu R, Xia Y, Li M, et al. Pim⁃1 as a therapeutic target in lupus nephritis［J］. Arthritis Rheumatol, 2019,71（8）:1308⁃1318. doi: 10.1002/art.40863.
［13］	Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus［J］. Ann Rheum Dis, 2019,78（9）:1151⁃1159. doi: 10.1136/annrheumdis⁃2018⁃214819.
［14］	Kaplan MJ, Radic M. Neutrophil extracellular traps: double⁃edged swords of innate immunity［J］. J Immunol, 2012,189（6）:2689⁃2695. doi: 10.4049/jimmunol.1201719.
［15］	Lood C, Blanco LP, Purmalek MM, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus⁃like disease［J］. Nat Med, 2016,22（2）:146⁃153. doi: 10.1038/nm.4027.
［16］	Moore S, Juo HH, Nielsen CT, et al. Role of neutrophil extracellular traps identify patients at risk of increased disease activity and cardiovascular comorbidity in systemic lupus erythematosus［J］. J Rheumatol, 2019. doi: 10.3899/jrheum.19 0875.
［17］	Langefeld CD, Ainsworth HC, Cunninghame Graham DS, et al. Transancestral mapping and genetic load in systemic lupus erythematosus［J］. Nat Commun, 2017,8:16021. doi: 10.1038/ncomms16021.
［18］	Reid S, Alexsson A, Frodlund M, et al. High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus［J］. Ann Rheum Dis, 2020,79（3）:363⁃369. doi: 10.1136/annrheumdis⁃2019⁃216227.
［19］	Searle SD, Mitnitski A, Gahbauer EA, et al. A standard procedure for creating a frailty index［J］. BMC Geriatr, 2008,8:24. doi: 10.1186/1471⁃2318⁃8⁃24.
［20］	Legge A, Kirkland S, Rockwood K, et al. Evaluating the properties of a frailty index and its association with mortality risk among patients with systemic lupus erythematosus［J］. Arthritis Rheumatol, 2019,71（8）:1297⁃1307. doi: 10.1002/art.40859.
［21］	Wise LM, Stohl W. The safety of belimumab for the treatment of systemic lupus erythematosus［J］. Expert Opin Drug Saf, 2019,18（12）:1133⁃1144. doi: 10.1080/14740338.2019.1685978.
［22］	Wallace DJ, Ginzler EM, Merrill JT, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus［J］. Arthritis Rheumatol, 2019,71（7）:1125⁃1134. doi: 10.1002/art.40861.
［23］	Davidson JE, Fu Q, Ji B, et al. Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis［J］. J Rheumatol, 2018,45（5）:671⁃677. doi: 10.3899/jrheum.161554.
［24］	Blankenship K. GlaxoSmithKline′s benlysta eyes lupus sales boost after kidney trial win［EB/OL］. ［2019⁃12⁃18］. https://www.fiercepharma.com/pharma/glaxosmithkline⁃s⁃benlysta⁃scores⁃trial⁃win⁃patients⁃lupus⁃nephritis.
［25］	Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First⁃Line Treatment of Follicular Lymphoma［J］. N Engl J Med, 2017,377（14）:1331⁃1344. doi: 10.1056/NEJMoa1614598.
［26］	Biogen Inc. Biogen announces positive phase 2 study results for cutaneous lupus erythematosus （CLE） and systemic lupus erythematosus （SLE）［EB/OL］.［2019⁃12⁃3］. http://investors.biogen.com/news⁃releases/news⁃release⁃details/biogen⁃announces⁃positive⁃phase⁃2⁃study⁃results⁃cutaneous⁃lupus.
［27］	Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus （TULIP⁃1）: a randomised, controlled, phase 3 trial［J］. Lancet Rheumatol, 2019, 1（4）: e208⁃e219. doi: 10.1016/S2665⁃9913（19）30076⁃1.
［28］	Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus［J］. N Engl J Med, 2020,382（3）:211⁃221. doi: 10.1056/NEJMoa1912196.
［29］	Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus［J］. J Clin Invest, 2019,129（3）:1359⁃1371. doi: 10.1172/JCI124466.
［30］	Roche Inc. FDA grants breakthrough therapy designation for Roche′s Gazyva （obinutuzumab） in lupus nephritis［EB/OL］. ［2019⁃9⁃18］. https://www.roche.com/media/releases/med⁃cor⁃2019⁃09⁃18.htm.
［31］	Mathian A, Pha M, Haroche J, et al. Withdrawal of low⁃dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial［J］. Ann Rheum Dis, 2020,79（3）:339⁃346. doi: 10.1136/annrheumdis⁃2019⁃216303.

[1]	罗帅寒天龙海陆前进, . 2023年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2024, 57(5): 468-471.
[2]	何艳艳马骁惠云王雯竹王宝玺曾荣徐浩翔. 基于高通量测序对反常性痤疮中PPAR通路作用的初步探讨[J]. 中华皮肤科杂志, 2024, 57(4): 309-315.
[3]	裴璐郑娜娜曾荣谢媛媛徐浩翔段志敏刘宇甄李岷. 痤疮丙酸杆菌生物膜诱导角质形成细胞发生炎症反应的分子机制研究[J]. 中华皮肤科杂志, 2024, 57(4): 302-308.
[4]	姚曼雪周乃慧. 程序性细胞死亡蛋白1/程序性细胞死亡蛋白配体1抑制剂相关的Stevens-Johnson综合征/中毒性表皮坏死松解症研究进展 [J]. 中华皮肤科杂志, 2024, 0(3): 20220644-e20220644.
[5]	陈星宇姚煦. 中性粒细胞在炎症性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220865-e20220865.
[6]	魏子妤杨勇. 离子通道与玫瑰痤疮发病机制的研究进展[J]. 中华皮肤科杂志, 2024, 57(2): 174-177.
[7]	渠莉田陈锦丛程波苏惠春. 特应性皮炎患者外周血单个核细胞转谷氨酰胺酶2的表达与相关炎症因子及疾病严重程度的相关性[J]. 中华皮肤科杂志, 2023, 56(7): 651-656.
[8]	连盼盼刘军苏忠兰王宏伟. 过氧化物酶体增殖物激活受体γ对皮肤生理功能和病理过程的影响[J]. 中华皮肤科杂志, 2023, 56(4): 365-368.
[9]	陈怡宋秀祖. 瞬时受体电位通道在黑素细胞中的作用及相关疾病研究[J]. 中华皮肤科杂志, 2023, 56(4): 376-379.
[10]	罗帅寒天龙海陆前进. 2022年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2023, 56(3): 266-269.
[11]	陈良宏孙艳王敬玉吴严. 本维莫德在皮肤病中的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20210875-e20210875.
[12]	黄文华郑振龙金哲虎. 转化生长因子β/Smad信号通路及相关影响因子在瘢痕疙瘩中的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220556-e20220556.
[13]	林子沅庞天怡武静文靳慧. 多环芳烃在炎症性皮肤病发生发展中的作用研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220271-e20220271.
[14]	王琪坚哲. 间充质干细胞三维培养技术及其在皮肤病治疗中的应用进展[J]. 中华皮肤科杂志, 2023, 0(2): 20230083-e20230083.
[15]	蒋佳怡王大光. 系统性疾病致甲改变机制研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220078-e20220078.

2019年系统性红斑狼疮研究新进展

Advances in systemic lupus erythematosus in 2019

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 31

相关文章 15

Metrics

本文评价

推荐阅读 10